← Back to Cohance Lifesciences Ltd. overview
Cohance Lifesciences Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,172 cr | ₹268 cr | ₹10.45 | ₹3,032 cr | ₹1,697 cr | 15.79% | 17.99% | 0.16x | 22.85% |
| FY2024 | ₹1,034 cr | ₹300 cr | ₹11.8 | ₹2,255 cr | ₹2,051 cr | 14.64% | 19.5% | 0.03x | 29.04% |
| FY2023 | ₹1,331 cr | ₹411 cr | ₹16.16 | ₹1,966 cr | ₹1,735 cr | 23.7% | 31.71% | 0.04x | 30.9% |
| FY2022 | ₹1,307 cr | ₹454 cr | ₹17.83 | ₹1,830 cr | ₹1,527 cr | 29.71% | 41.48% | 0.06x | 34.72% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.